Latest News
Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals shifts focus to oncology with new product VEPPANU targeting $1B breast cancer market.
- Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine (NASDAQ:RIGL)
- Rigel Pharmaceuticals to unveil RET fusion-positive tumor findings at ESMO 2026
- Missed Rigel Pharmaceuticals' Rally? Here's What Early Buyers Saw
- Rigel Pharmaceuticals, Inc. Highlights New GAVRETO® (Pralsetinib) Data Across RET Fusion-Positive Cancers At ESMO Congress 2026
- Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
- Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Headlines from the last 30 days, linking to the original publishers. See all market news →